|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical and Biotech Licensing Strategies - Driving Revenue through Partnerships
CBR Pharma Insights, Jan 2011, Pages: 55
In today’s pharmaceutical industry, multiple factors - looming patent expirations, depleted pipelines, increases in R&D expenditures, payer pressures, and tighter FDA regulations- have forced Big Pharma to change its business model. The evolving model is one grounded in collaboration. Companies are no longer relying solely on their own internal R&D programs for innovation; they are looking outside of their four walls. Some have labeled this ‘search and development’.
There are many types of alliances that support this collaborative model. One type, in-licensing products, is very appealing. The number of licensing agreements has grown year over year since 2007. The top companies are interested in several key therapeutic areas including oncology, CNS, and infectious disease. These companies are also more focused on products in the early phases of development.
This consultancy-style report focuses on licensing activity in 2010, the trends that we’re seeing in the changing pharmaceutical environment, and the motivations for companies – on both sides – to do deals in recent years.
Reasons to Purchase
- Gain access to a fully sourced, executive assessment of the trends within pharmaceutical & biotech licensing activity and how those trends support company growth
- Identify who the leading companies are from an in-license & out-license point of view and if they are keeping to their overall corporate strategy
- Benefit from CBR’s case study analysis which supports the various motivations companies have to engage in licensing activity
- Understand the key issues driving the changes that are being seen within the pharmaceutical industry and why new business models are evolving to support continued revenue growth
|
|
|
|
